Finance

Lists
MGX:NASDAQ
Metagenomi Therapeutics Inc
1,00 US$
+0,68%
(+0,0068) 1D
1,00 US$
0,00% (0,00)
After hours
Closed: 9 ოქტ, 16:00:01 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for MGX...
Open
0,99 US$
High
1,04 US$
Low
0,99 US$
Mkt. cap
37,90 მლნ.
Avg. vol.
156,74 ათ.
Volume
147,18 ათ.
52-wk high
3,95 US$
52-wk low
0,96 US$
EPS
-2,49 US$
Shares outstanding
37,78 მლნ.
No. of employees
113
Open
0,99 US$
High
1,04 US$
Low
0,99 US$
Mkt. cap
37,90 მლნ.
Avg. vol.
156,74 ათ.
Volume
147,18 ათ.
52-wk high
3,95 US$
52-wk low
0,96 US$
EPS
-2,49 US$
Shares outstanding
37,78 მლნ.
No. of employees
113
News stories
From web sources and news partners
About Metagenomi Therapeutics Inc
CEO-
Employees113
Founded2016
HeadquartersEmeryville, კალიფორნია, ამერიკის შეერთებული შტატები
Sector-
Websitemetagenomi.co
Analyst ratings
Based on 4 analysts giving stock ratings to MGX in the past 3 months
Strong buy
Buy
3
Hold
1
Sell
0
12-month forecast
Based on 4 Wall Street analysts offering 12 month price targets for MGX in the last 3 months.
Highest
Current 1,00 US$
7,00 US$ (+600,00%)
Average
6,00 US$ (+500,00%)
Lowest
5,00 US$ (+400,00%)
Analyst
Recommendation
Action
Price target
Projected
Date
Unknown Analyst
J.P. Morgan
Hold
Maintained
-
-
08/17/2026
Joseph Thome
TD Cowen
Buy
Maintained
-
-
08/11/2026
Yanan Zhu
Wells Fargo
Buy
Reiterated
7,00 US$
+600%
08/11/2026
Keay Nakae
Chardan Capital
Buy
Maintained
5,00 US$
+400%
08/10/2026
Geulah Livshits
Chardan Capital
Buy
Maintained
5,00 US$
+400%
07/07/2026
Last report
10 აგვ. 2026
Fiscal period
Q2 2026
-0,73 US$ / -0,52 US$
-40,38%miss
Revenue / Est. (USD)
-257,00 ათ. / 2,93 მლნ.
-108,76%miss
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
8,66 მლნ.
3,91 მლნ.
1,25 მლნ.
-257,00 ათ.
Cost of goods sold
25,28 მლნ.
21,50 მლნ.
19,30 მლნ.
22,51 მლნ.
Cost of revenue
25,28 მლნ.
21,50 მლნ.
19,30 მლნ.
22,51 მლნ.
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
6,22 მლნ.
6,78 მლნ.
6,54 მლნ.
6,00 მლნ.
Operating expense
6,22 მლნ.
6,78 მლნ.
6,54 მლნ.
6,00 მლნ.
Total operating expenses
31,50 მლნ.
28,28 მლნ.
25,84 მლნ.
28,52 მლნ.
Operating income
-22,84 მლნ.
-24,37 მლნ.
-24,59 მლნ.
-28,77 მლნ.
Other non operating income
-2,00 ათ.
-11,00 ათ.
-1,00 ათ.
35,00 ათ.
EBT including unusual items
-20,63 მლნ.
-22,49 მლნ.
-23,05 მლნ.
-27,48 მლნ.
EBT excluding unusual items
-20,63 მლნ.
-22,49 მლნ.
-23,05 მლნ.
-27,48 მლნ.
Income tax expense
-234,00 ათ.
34,00 ათ.
10,00 ათ.
-
Effective tax rate
1,13%
-0,15%
-0,04%
-
Other operating expenses
-
-
-
-
Net income
-20,39 მლნ.
-22,53 მლნ.
-23,06 მლნ.
-27,48 მლნ.
Net profit margin
-235,51%
-576,02%
-1 847,68%
10 693,39%
Earnings per share
-0,55
-0,60
-0,61
-0,73
Interest and investment income
2,21 მლნ.
1,88 მლნ.
1,54 მლნ.
1,26 მლნ.
Interest expense
-
-
-
-
Net interest expenses
2,21 მლნ.
1,88 მლნ.
1,54 მლნ.
1,26 მლნ.
Depreciation and amortization charges
-
-
-
-
EBITDA
-21,52 მლნ.
-23,07 მლნ.
-23,31 მლნ.
-27,51 მლნ.
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google აპები